|Bid||25.50 x 900|
|Ask||26.50 x 1000|
|Day's Range||25.38 - 26.30|
|52 Week Range||11.15 - 33.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.67|
Neither the CRISPR/Cas9 start-up nor its gene-editing peers had much to say last month, but it only took a suggestion of positive signs from elsewhere to send them rocketing higher.
Intellia Therapeutics, Crispr Therapeutics and Editas Medicine are at the forefront of the new CRISPR gene editing technology, which could cure thousands of diseases.
CAMBRIDGE, Mass., Jan. 31, 2018-- Intellia Therapeutics, Inc., a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one ...
NEW YORK, Dec. 20, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intellia ...
Leonard has successfully led the development and regulatory approval of breakthrough biopharmaceuticals Company’ s pipeline continues to advance toward clinical development. CAMBRIDGE, Mass., Dec. 18, ...
Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin Approximately 80-95 percent editing was achieved in CD34+ cells Increased fetal hemoglobin ...
Healthcare won't be the same in the future because of these pioneers in gene editing, gene sequencing, and artificial intelligence.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Intellia Therapeutics, Inc. a score of 56. Our analysis is based on comparing Intellia Therapeutics, Inc. with the following peers – Plandai Biotechnology, Inc., Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc. and Bioblast Pharma Ltd. (PLPL-US, PIRS-US, PDLI-US and ORPN-US). Investment Outlook Intellia Therapeutics, Inc. has a fundamental ... Read more (Read more...)
Intellia Therapeutics saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering.
NEW YORK, NY / ACCESSWIRE / October 31, 2017 / Intellia Therapeutics, Inc. (NASDAQ: NTLA ) will be discussing their earnings results in their Q3 Earnings Call to be held on October 31, 2017 at 8:30 AM ...